Core Viewpoint - The announcement by the company regarding its inhalation solution for human interferon α1b being included in the list of breakthrough therapies by the National Medical Products Administration indicates a significant step in addressing respiratory syncytial virus (RSV) infections in children, although it will not have a major impact on the company's recent performance [1] Group 1: Product Development - The inhalation solution is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - The indication for the product is for pediatric lower respiratory tract infections caused by RSV, including pneumonia and bronchiolitis [1] - As of the announcement date, the product is in the Phase III clinical trial stage [1] Group 2: Market Context - According to a study published in The Lancet, there were 33 million cases of acute lower respiratory infections caused by RSV in children under five globally in 2019 [1] - The inclusion of the product in the breakthrough therapy list reflects its potential significance in the market, although future research progress, results, and competitive landscape remain uncertain [1]

证券代码：688136 证券简称：科兴制药 公告编号：2025-078 科兴生物制药股份有限公司 自愿披露关于人干扰素α1b 吸入溶液 纳入突破性治疗品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科兴药业 有限公司（以下简称"深圳科兴"）自主研发的人干扰素α1b吸入溶液已被国家 药品监督管理局药品审评中心（以下简称"药审中心"）纳入突破性治疗品种名 单，近日已完成公示，现将主要情况公告如下： 二、药品的其他相关情况 干扰素（interferon，IFN）是一类具有广谱抗病毒、抗肿瘤和免疫调节作 用的蛋白质，是机体天然免疫的关键组成部分。人干扰素α1b吸入溶液是公司在 抗病毒领域的又一大突破，该药品属儿童专用药，通过雾化给药，有效成分可以 直达病灶，起效更快，相比注射剂，儿童患者无需承受注射的疼痛，接受度和安 全性更高。 公司人干扰素α1b吸入溶液适应症为小儿呼吸道合胞病毒性下呼吸道感染 （肺炎、毛细支气管炎）。呼吸道合胞病毒（RSV）是引起婴幼儿急 ...

Core Viewpoint - The announcement highlights that the company's subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has developed an inhalation solution of human interferon α 1b, which has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration's Drug Review Center [1] Group 1: Product Development - The inhalation solution is a significant breakthrough in the antiviral field, specifically designed for children [1] - The product is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly compared to injection [1] - The solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] Group 2: Advantages of the Product - The inhalation method eliminates the pain associated with injections, leading to higher acceptance and safety for pediatric patients [1] - The broad-spectrum antiviral, antitumor, and immune-regulating properties of interferon make it a key component of the body's natural immunity [1]

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α 1b, developed by the company's wholly-owned subsidiary, has been included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Development - The human interferon α 1b inhalation solution is a significant breakthrough in the antiviral field for the company [1] - This medication is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - Compared to injectable forms, this inhalation solution offers higher acceptance and safety for pediatric patients, as they do not have to endure the pain of injections [1] Group 2: Indications and Applications - The indication for the human interferon α 1b inhalation solution is for pediatric respiratory syncytial virus (RSV) lower respiratory tract infections, including pneumonia and bronchiolitis [1]

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α1b, developed by the wholly-owned subsidiary of the company, has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 1: Product Development - The inhalation solution is intended for the treatment of pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] - As of the date of the announcement, the human interferon α1b inhalation solution is in the Phase III clinical trial stage [1] Group 2: Company Actions - The company will actively promote the research and development project and fulfill its information disclosure obligations in a timely manner [1]

资料显示，科兴生物制药股份有限公司位于山东省济南市章丘区埠村街道创业路2666号,广东省深圳市 南山区高新中一道与科技中一路交汇处创益科技大厦19楼，成立日期1997年8月22日，上市日期2020年 12月14日，公司主营业务涉及从事重组蛋白药物和微生态制剂的研发、生产、销售。主营业务收入构成 为：医药产品97.38%，其他2.62%。 从基金十大重仓股角度 数据显示，华泰保兴基金旗下1只基金重仓科兴制药。华泰保兴科荣A（009124）二季度持有股数2.1万 股，占基金净值比例为1.59%，位居第八大重仓股。根据测算，今日浮亏损失约4.28万元。 华泰保兴科荣A（009124）成立日期2020年5月11日，最新规模2080.67万。今年以来收益7.86%，同类 排名6091/8172；近一年收益13.4%，同类排名6506/7995；成立以来收益34.16%。 华泰保兴科荣A（009124）基金经理为周咏梅、陈祺伟。 9月23日，科兴制药跌5.03%，截至发稿，报38.50元/股，成交1.33亿元，换手率1.68%，总市值77.48亿 元。 截至发稿，周咏梅累计任职时间7年232天，现任基金资产总规模88.9 ...

Market Overview - On September 22, the biopharmaceutical sector experienced a slight decline of 0.15%, with Kanglaosheng leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aipumai (688293) with a closing price of 58.70, up 9.90% on a trading volume of 47,100 shares and a turnover of 267 million yuan [1] - Baipusais (301080) closed at 61.75, up 5.05% with a trading volume of 38,300 shares and a turnover of 231 million yuan [1] - Muli Pharmaceutical (603087) closed at 73.60, up 3.76% with a trading volume of 182,000 shares and a turnover of 134.2 million yuan [1] - Conversely, the following stocks saw significant declines: - Kanglaosheng (833575) closed at 14.71, down 6.90% with a trading volume of 90,400 shares and a turnover of 137 million yuan [2] - Kexing Pharmaceutical (688136) closed at 40.54, down 3.20% with a trading volume of 47,600 shares and a turnover of 194 million yuan [2] - Changchun High-tech (000661) closed at 122.10, down 2.49% with a trading volume of 102,800 shares and a turnover of 1.265 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 473 million yuan from institutional investors, while retail investors contributed a net inflow of 418 million yuan [2] - The following stocks had notable capital flows: - Ganli Pharmaceutical (603087) had a net inflow of 58.16 million yuan from institutional investors [3] - Rongchang Biotechnology (688331) saw a net inflow of 43.73 million yuan from institutional investors [3] - ZhiXiangJinTai (688443) had a net inflow of 6.53 million yuan from retail investors [3]

中国经济网北京9月22日讯 科兴制药（688136.SH）近日披露《股东询价转让结果报告书暨持股5% 以上股东权益变动触及5%整数倍的提示性公告》及《简式权益变动报告书》。 根据公告，深圳科益医药控股有限公司（以下简称"科益医药"）于2025年8月5日通过询价转让减持 公司股份6,037,717股，占公司总股本的3.00%；于2025年9月19日通过询价转让减持公司股份10,062,800 股，占公司总股本的5.00%。 此外，2025年7月7日，科益医药通过集中竞价减持1,994,700股；2025年7月8日至2025年7月9日，科 益医药通过大宗交易减持219,500股；合计减持2,214,200股。科益医药及其一致行动人邓学勤合计持股 比例由65.00%减少至55.38%，累计权益变动比例触及5%的整数倍。 科益医药合计减持公司股份18,314,717股，根据减持期间股价均价46.60元计算，套现总金额约 853,465,812.2元。 | 信息披露 义务人 | 权益变动 方式 | 变动日期 | 股份种类 | 变动股数 (股) | 变动比例 (%) | | --- | --- | --- | --- | ...

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Core Viewpoint - The recent share transfer by Kexing Pharmaceutical indicates a strategic move towards preparing for a potential IPO in Hong Kong, with significant capital operations involving both share reduction by the controlling shareholder and bond issuance by the company [1][2][3] Group 1: Share Transfer Details - Kexing Pharmaceutical's controlling shareholder, Koyi Medicine, transferred 10.0628 million unrestricted shares at a price of 30.88 yuan per share, totaling approximately 311 million yuan, which represents 5% of the total share capital [1] - The transfer price reflects a nearly 30% discount compared to the average price over the previous 20 trading days and a significant drop from the 36.7 yuan per share price in early August [1] - The effective subscription multiple was only 1.01 times, indicating weak demand from institutional investors [1] Group 2: Financial Performance and Future Plans - Koyi Medicine has raised a total of 754 million yuan through various share reduction methods over the past three months [1] - Kexing Pharmaceutical plans to issue up to 800 million yuan in technology innovation bonds, creating a dual funding flow strategy of shareholder reduction and corporate bond issuance [1][2] - The company reported a net profit of 80.3445 million yuan in the first half of the year, a year-on-year increase of 576.45%, with cash flow from operating activities turning positive [2] Group 3: Market Implications and Investor Sentiment - The high discount and rapid pace of share reduction suggest a pressing need for cash by the controlling shareholder and a cautious outlook on short-term stock price movements [2][3] - Koyi Medicine's shareholding has decreased from 66.01% to 54.5%, still above the 25% public holding requirement for Hong Kong listings, indicating that further share distribution will be necessary for a successful IPO [2] - The introduction of 35 institutional investors through the share transfers enhances the diversity and stability of the company's shareholder structure, potentially boosting confidence among international investors for the upcoming IPO [2]